Previous results suggest that especially neuroendocrine tumor cell lines with low (i.e. BON-1) or intermediate (i.e. NCI-H727 and TT cells) SSTR2 levels are susceptible to epigenetic treatment, whereas upregulation in neuroendocrine tumor cell lines with high SSTR2 levels is less effective (i.e. GOT-1 and MZ-CRC-1 cells) 16, 20. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.